New eye injection aims to slow vision loss from Age-Related macular degeneration
NCT ID NCT06970665
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the safety of a drug called ASP3021 (avacincaptad pegol) for people in Japan with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. Twenty participants will receive monthly injections into the affected eye for 12 months. The main goal is to see if the treatment is safe and well-tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avacincaptad pegol (ASP3021, IZERVAY)
What this could lead to
If successful, this could confirm that ASP3021 is safe for Japanese patients with geographic atrophy, potentially slowing vision loss.
What could go wrong
This is a small, single-arm safety study with only 20 participants, so results may not apply broadly. Side effects from eye injections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fukushima Medical University Hospital
RECRUITINGFukushima, Fukushima, Japan
-
Jichi Medical University Hospital
RECRUITINGShimotsuke-shi, Tochigi, Japan
-
Kagawa University Hospital
RECRUITINGKita-gun, Kagawa-ken, Japan
-
Kansai Medical University Hospital
RECRUITINGHirakata-shi, Osaka, Japan
-
Kyoto University Hospital
RECRUITINGKyoto, Kyoto, Japan
-
Mie University Hospital
RECRUITINGTsu, Mie-ken, Japan
-
Nagasaki University Hospital
RECRUITINGNagasaki, Nagasaki, Japan
-
Nagoya City University Hospital
RECRUITINGNagoya, Aichi-ken, Japan
-
Nihon University Hospital
RECRUITINGChiyoda-ku, Tokyo, Japan
-
Seirei Hamamatsu General Hospital
RECRUITINGHamamatsu, Shizuoka, Japan
-
The University of Osaka Hospital
RECRUITINGSuita-shi, Osaka, Japan
-
Tokyo Women's Medical University Hospital
RECRUITINGShinjuku-ku, Tokyo, Japan
-
Toyama University Hospital
RECRUITINGToyama, Toyama, Japan
-
University Of Yamanashi Hospital
RECRUITINGChuo-shi, Yamanashi, Japan
-
University of the Ryukyus hospital
RECRUITINGGinowan-shi, Okinawa, Japan
-
Yokohama City University Medical Center
RECRUITINGYokohama, Kanagawa, Japan